Google_______________

Report of Hepatitis C Virus Genotype Recombination

By Liz Highleyman

Hepatitis C virus (HCV) genotype is an important factor that influences response to antiviral therapy. HCV genotypes 2 and 3 respond better to interferon-based therapy, while genotype 1 (and possibly 4) is more difficult to treat.

In the January 31, 2007 online edition of the Journal of Virology, French researchers described a strain of HCV that appears to combine 2 previously recognized genotypes.

The 9.2 kb sequence of an HCV strain found in Southwest France was compared to those of reference strains in HCV sequence databases. The investigators discovered a recombinant virus with genotype 2 at the 5' end and genotype 5 at the 3' end. The crossover point was located between genes NS2 and NS3.

"Recombination between HCV genotypes must now be considered in studies on HCV virus epidemiology and evolution, and predictions of the virus response to antiviral therapy," the authors concluded. "The location of the recombination point may also be useful for constructing infectious chimeric viruses."

02/16/07

Reference
F LeGrand-Abravanel, J Claudinon, F Nicot, and others. A new natural intergenotypic (2/5) recombinant of Hepatitis C virus. Journal of Virology. January 31, 2007 [Epub ahead of print].

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-approved
Monotherapies for HCV
Intron A
Roferon

Infergen

Pegasys

PEG-Intron

FDA-approved
Combination
Therapies
for HCV
Pegasys + Copegus
PEG-Intron + Rebetol
Intron A + Rebetol
Roferon A + Ribavirin
Index of All
Hepatitis C Articles
by Topic ( A to Z)